Average body-weight reduction in the pivotal trials. Individual results vary; these are trial means at the maintenance dose.
Source: Once-Weekly Semaglutide in Adults with Overweight or Obesity — NEJM, 2021
Source: Tirzepatide Once Weekly for the Treatment of Obesity — NEJM, 2022
Myth
GLP-1s are only for people with type 2 diabetes.
Fact
Wegovy and Zepbound are FDA-approved for chronic weight management at BMI ≥30 (or ≥27 with a comorbidity). Diabetes is one indication, not the only one.
FDA Wegovy prescribing informationMyth
You regain everything the moment you stop.
Fact
STEP-1 extension data show ~67% of weight lost is regained in the 12 months after stopping semaglutide — significant, but not 100%, and trial participants who maintained lifestyle changes regained less.
STEP-1 extension, NEJM 2022Myth
Compounded semaglutide is illegal everywhere in 2026.
Fact
After the FDA declared the branded shortage resolved in 2025, mass identical-copy compounding ended. Personalized compounded formulations from licensed 503A pharmacies remain available for individual patient needs.
FDA Compounded Drug Q&A“The provider you pick matters less than whether your prescriber catches the side-effect dose-titration window. The standard 0.25 → 2.4 mg ramp over 16 weeks exists for a reason — patients who skip steps are the ones who quit.”
Average outcomes from the pivotal FDA registrational trials for the GLP-1 drugs these providers prescribe. Individual results vary; trial conditions don't equal real-world clinic conditions.
STEP 1 trial — Wegovy
In the 68-week STEP 1 trial, participants on semaglutide 2.4 mg lost an average of 14.9% of body weight versus 2.4% on placebo. 50.5% reached ≥15% weight loss; 32.0% reached ≥20%.
SURMOUNT-1 trial — Zepbound
In the 72-week SURMOUNT-1 trial, tirzepatide 15 mg participants lost 20.9% of body weight versus 3.1% on placebo. 91% achieved ≥5% weight loss; 56.7% achieved ≥20%.
STEP 3 trial — Wegovy + IBT
STEP 3 paired semaglutide 2.4 mg with intensive behavioral therapy. At 68 weeks, mean weight loss was 16.0% versus 5.7% on placebo + IBT. Counseling-included programs replicate this arm.
Ranked & reviewed
The best GLP-1 telehealth providers in 2026 are Found, Hims, Ro, and Sequence, ranked by a weighted score of pricing (35%), user experience (25%), medication variety (20%), and insurance acceptance (20%). All four ship FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound directly from licensed U.S. pharmacies.
Updated June 2026
Affiliate disclosure: we earn commission on signups. Editorial ranking stays independent.
Why trust this ranking
At-a-glance pricing
| Provider | Starting price | Accepts insurance | |
|---|---|---|---|
| Sequence (Weight Watchers Clinic) | $99.00/mo | ✓ | Visit → |
| Sesame Care | $59.00/mo | — | Visit → |
| Found | $99.00/mo | — | Visit → |
| Ro | $99.00/mo | — | Visit → |
How we tested: We audited 10 GLP-1 telehealth providers across 4 buyer personas (cash-pay, insurance, no-needles, fast-start), then verified each ranking with a licensed clinician.
Full methodology: /how-we-rank. Weights re-evaluated quarterly with editorial sign-off.
| LifeMD | $249.00/mo | ✓ | Visit → |
| Hims | $79.00/mo | — | Visit → |
| Push Health | $75.00/mo | — | Visit → |
| Noom | $149.00/mo | — | Visit → |
| Henry Meds | $179.00/mo | — | Visit → |
| TrimRX | $179.00/mo | — | Visit → |
Starting prices reflect provider-published rates at most-recent editorial review; programs change without notice — verify on the provider site before signup. Affiliate disclosure: we earn commission on signups via Visit links.
Weight Watchers-owned medical weight loss platform combining GLP-1s with coaching.
Marketplace pricing — book a licensed clinician directly, medication filled through their pharmacy of choice.
Personalized weight-loss program offering GLP-1s plus non-GLP-1 alternatives.
Direct-to-consumer GLP-1 program with broad medication selection and a polished app.
Full primary-care telehealth with GLP-1 — the pick for patients who want ongoing PCP integration.
Telehealth platform with GLP-1 weight loss as part of a broader wellness lineup.
Direct-to-doctor GLP-1 access — no subscription, pay per visit + medication.
Behavioral-first program with GLP-1 access — coaching bundled in for adherence-heavy users.
Compounded-first GLP-1 telehealth with three-tier pricing — the cash-only value pick.
Cash-pay online GLP-1 program from $179/mo — compounded semaglutide + tirzepatide.
Editor's pick
Sequence (Weight Watchers Clinic) doesn't dominate one category — instead it ranks in the top quartile for price, experience, medication variety, and insurance acceptance simultaneously. The 35/25/20/20 weighting picks the provider that's least likely to have a hidden weakness.
Wide formulary means you can switch agents without changing providers — useful when your insurance changes or a drug enters shortage.
Our editorial team confirms each ranked provider operates under licensed US prescribers and ships from registered pharmacies. Our commission is disclosed; ranking is independent of affiliate terms.
Ranking methodology
Formula applies identically to every provider regardless of affiliate payout.
We weight four factors transparently: pricing (35%), user experience (25%), medication variety (20%), and insurance acceptance (20%). Full methodology is published at /how-we-rank — no provider can pay for a higher rank.
We earn affiliate commission when readers sign up through our links. The commission does not affect rank order. Our scoring formula is published and the same formula is applied to every provider, including ones we do not have an affiliate partnership with.
Quarterly. We re-pull every provider’s current pricing, medication list, state availability, and insurance acceptance before each refresh. Major changes (new drug approval, manufacturer-direct pricing shift, FDA shortage status) trigger an off-cycle update with a published changelog.
Most ranked providers prescribe at least one branded GLP-1 (Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, or Rybelsus). Medication availability varies by state, BMI eligibility, and current FDA shortage status. Each provider’s page lists exactly which medications they currently dispense.
Cash-pay GLP-1 telehealth ranges from roughly $349/month (manufacturer-direct programs like LillyDirect for Zepbound vials, NovoCare Pharmacy for Wegovy) up to $1,300/month for branded pens through some retail-pharmacy channels. Membership fees ($25-$99/month) and labs are usually billed separately from the medication itself.
Some providers (Found, Sequence, Calibrate) bill insurance directly; others (Ro, Hims) operate cash-pay only and provide a superbill you can submit yourself. Coverage depends on your insurer’s formulary, BMI eligibility, prior-authorization requirements, and whether the drug is approved for weight management or only type 2 diabetes under your plan.
For semaglutide: the FDA declared the injection shortage resolved in February 2025, so mass identical-copy 503A compounding ended. For tirzepatide: shortage resolved December 2024 with a wind-down window through 2025. Personalized compounded formulations from licensed 503A pharmacies remain available for documented individual patient needs.
Most ranked providers offer a money-back guarantee on unused medication or first-month membership. Switching between providers is straightforward — most accept records from another telehealth provider without requiring a new in-person consult. See our /switching guides for medication-specific dose-equivalence and washout protocols.
Affiliate disclosure: We earn commissions when readers sign up through our links. This does not affect our editorial ranking. See our methodology →